Research lines

• Early-phase and investigator-initiated clinical trials

  We design and conduct early-phase clinical trials and investigator-initiated studies to evaluate novel targeted agents and immunotherapies. Close collaboration between clinicians and translational researchers ensures rapid and efficient translation of laboratory discoveries into clinical testing.

• Molecular profiling and biomarker discovery in upper gastrointestinal cancers

  We perform comprehensive molecular and transcriptomic profiling of gastric, pancreatic, and biliary tract tumors to identify oncogenic drivers and predictive biomarkers of response or resistance. By integrating clinical and molecular data, we aim to improve patient stratification and guide precision medicine approaches in upper GI cancers. Additionally, we coordinate and participate in national and international multicenter clinical trials assessing new therapeutic strategies for upper GI cancers. Simultaneously, we conduct translational studies to identify and validate prognostic and predictive biomarkers that inform clinical decision-making.

• Liquid biopsy for real-time tumor monitoring

  We develop and validate liquid biopsy technologies that detect tumor-derived nucleic acids in plasma, enabling non-invasive monitoring of tumor dynamics, minimal residual disease, and treatment response. This method allows real-time tracking of resistance mechanisms and supports more adaptive, personalized therapeutic strategies.

• Patient-derived and genetically engineered models

  We create patient-derived organoids, xenografts (PDXs), and genetically engineered mouse models that replicate the heterogeneity of upper GI tumors. These models are crucial for studying tumor biology, understanding mechanisms of drug resistance, and testing novel therapeutic strategies before clinical use.

• Upper GI cancer cell and stromal interactions

  We investigate how interactions among tumor cells, the immune system, and stromal components affect tumor progression and therapy resistance. Understanding these complex networks may reveal new therapeutic opportunities and enhance the effectiveness of immunotherapy in upper GI cancers.